Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer

• DOI: 10.1200/jco.2004.08.065
• Publication Date: 2004-04-29T22:34:18Z
• Authors: Howard Burris; Denise Yardley; Suzanne Jones; Gerry Houston; Catherine Broome; Dana Thompson; F. Anthony Greco; Melissa White; John Hainsworth
• Keywords: Carboplatin

Purpose To determine the response rate of trastuzumab as first-line therapy in patients with HER-2 overexpressing metastatic breast cancer. assess feasibility and toxicity weekly paclitaxel/carboplatin or without following initial treatment trastuzumab. Patients Methods Sixty-one received (8 mg/kg followed by 4 mg/kg/wk) for 8 weeks. Responding additional weeks (4 mg/kg/wk), then proceeded to receive (2 mg/kg) combination paclitaxel 70 mg/m 2 carboplatin (area under curve, 2) 6 rest. Stable after trastuzumab, paclitaxel, carboplatin. disease progression during had discontinued were treated paclitaxel/carboplatin. Results Weekly was well tolerated. Fifty-two assessable all 61 survival. Seventeen (33%) 52 experienced a minor/partial single-agent Fifteen (29%) stable paclitaxel/carboplatin/trastuzumab. Thirty-one measurable An overall 84% (eight complete responses/18 partial responses), median time 14.2 months, survival 32.2 months reported triplet combination. In alone on an 69% (one response/10 8.3 22.2 reported. Median is 10 26.7 months. Conclusion This trial confirms activity tolerability women